Year-end cash, cash equivalents, and marketable securities were $1.1 billion as of December 31, 2025, reaffirming a cash runway into Q1 2028. Positive topline results were reported from the Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 skip amenable Duchenne muscular dystrophy (DMD), demonstrating a statistically significant 7-fold increase in muscle content-adjusted dystrophin expression to 5.46% of normal at six months (p<0.0001). Improvement relative to placebo was observed across all six prespecified topline functional endpoints for z-rostudirsen, with Time to Rise (TTR) Velocity and 10-Meter Walk/Run (10MWR) Velocity showing improvement with a nominal p<0.05. Lung function, as measured by Forced Vital Capacity Percent Predicted (FVC%p), was preserved at 6 months with z-rostudirsen compared to a decline in placebo. Z-rostudirsen continued to demonstrate a favorable safety profile, with most related treatment emergent adverse events (TEAEs) being mild or moderate. A Biologics License Application (BLA) for U.S. Accelerated Approval of z-rostudirsen is planned for submission in Q2 2026, with a potential U.S. launch in Q1 2027. Enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE trial of z-basivarsen in myotonic dystrophy type 1 (DM1) is expected to complete in Q2 2026. Data from the z-basivarsen ACHIEVE REC are planned for Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in early Q3 2027, with a potential U.S. launch in Q1 2028. Four new development candidates (DYNE-253, DYNE-245, DYNE-244, and DYNE-255) for DMD amenable to skipping of exons 53, 45, 44, and 55, respectively, are advancing into IND-enabling studies. Net loss for the year ended December 31, 2025, was $446.2 million, compared to $317.4 million for the year ended December 31, 2024.